Big pharma: a story of success in a market economy [Book Review]
David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Medicine, Health Care and Philosophy 16 (2):305-309 (2013)
In this paper, I will argue that the current discussions about regulating certain activities concerning the pharmaceutical industry do miss a crucial point. The Pharmaceutical Industry is a story of success, providing a wealth of new discoveries and applied technologies, which have greatly enhanced our lives. The current call for strict regulation of the Pharmaceutical Industry makes the unwarranted assumption that such regulation will not disturb the mechanisms of the Industry’s success. I will claim that a centralised regulation profoundly transforms the direction of travel. I will also claim that the role of the executive in bypassing regulations creates a parallel industry of subsidiary regulations to counter such bypassing. The predictable consequence is the increasing role of central regulatory control and the progressive slowing down of the success of the Pharmaceutical Industry leading towards an undesirable mediocrity. The conclusion I wish to advance is that our choices are not limited to ‘a wild open market’ and ‘a regulated open market’ scenarios, and the strategy to avoid a robustly regulated but mediocre Pharmaceutical Industry may involve ‘non-open market scenarios’ which have so far been absent from the alternatives discussed
|Keywords||Bureaucracy Central planning Executive role/motivation/behaviour Ideology Pharmaceutical industry Political economy of health Regulation|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Stephan Sahm (2013). On Markets and Morals—(Re-)Establishing Independent Decision Making in Healthcare: A Reply to Joao Calinas-Correia. [REVIEW] Medicine, Health Care and Philosophy 16 (2):311-315.
David Badcott (2013). Big Pharma: A Former Insider's View. [REVIEW] Medicine, Health Care and Philosophy 16 (2):249-264.
Richard T. de George (2005). Intellectual Property and Pharmaceutical Drugs. Business Ethics Quarterly 15 (4):549-575.
Shaili Jain (2007). Understanding Physician-Pharmaceutical Industry Interactions. Cambridge University Press.
John T. Fielding (1999). Dangerous Medicine: The Pharmaceutical Industry's Questionable Ethical Practices. Dissertation, Salve Regina University
Sean Ekins & Richard J. McGowan (2002). Postgraduate Education and the Changing Interaction with the Pharmaceutical Industry: A Cross-Cultural Perspective. [REVIEW] Foundations of Science 7 (4):413-424.
Włodzimierz Kubiak (2005). Medicine and Pharmacy — Facts and Myths About the Development of an Innovative Pharmaceutical Industry in Poland. Science and Engineering Ethics 11 (1):41-51.
Iain A. Davies (2009). Alliances and Networks: Creating Success in the UK Fair Trade Market. [REVIEW] Journal of Business Ethics 86 (1):109 - 126.
Frauke Druckrey (1998). How to Make Business Ethics Operational: Responsible Care – an Example of Successful Self-Regulation? [REVIEW] Journal of Business Ethics 17 (9-10):979-985.
Joanne Sneddon & Bernard Rollin (2010). Mulesing and Animal Ethics. Journal of Agricultural and Environmental Ethics 23 (4):371-386.
Chin Pang Cheng, Gloria T. Lau, Kincho H. Law, Jiayi Pan & Albert Jones (2008). Regulation Retrieval Using Industry Specific Taxonomies. Artificial Intelligence and Law 16 (3):277-303.
Gloria Chin Pang Cheng, Kincho T. Lau, Jiayi Pan H. Law & Albert Jones (2008). Regulation Retrieval Using Industry Specific Taxonomies. Artificial Intelligence and Law 16 (3).
Added to index2012-03-07
Total downloads12 ( #184,411 of 1,696,808 )
Recent downloads (6 months)2 ( #250,888 of 1,696,808 )
How can I increase my downloads?